South Korea to resume wider use of AstraZeneca coronavirus jab

South Korea will resume vaccination of people under 60 with AstraZeneca jab, the Korean Disease Control and Prevention Agency (KDCA) said in a statement, Report informs citing Reuters.

People under 30 will still be excluded from the vaccinations resuming on Monday because the benefits of the shot do not outweigh the risks for that age group, the KDCA said.

South Korea Wednesday suspended providing the AstraZeneca shot to people under 60 as Europe reviewed cases of blood clotting in adults.

People under 30 will still be excluded from the vaccinations resuming on Monday because the benefits of the shot do not outweigh the risks for that age group, the Korea Disease Control and Prevention Agency (KDCA) said in a statement.

Three vaccinated people in South Korea are reported to have developed blood clots, with one case determined to be correlated to the vaccine, Choi Eun-hwa, chair of the Korea Advisory Committee on Immunisation Practices, told a briefing.

That case was a type of blood clot considered less serious than the type being examined by European authorities, she said.

For most people, the risks of coronavirus are far worse than the rare possibility of side effects from the vaccines, Choi said, adding that the best way to end the pandemic was to vaccinate everyone who can receive it.

But she said, “the benefits are not as great for those under 30 years old, so we will not recommend the AstraZeneca vaccine for them.”